MBF 015
Alternative Names: MBF-015Latest Information Update: 04 Jul 2024
At a glance
- Originator Medibiofarma
- Class Amides; Antineoplastics; Heterocyclic compounds; Small molecules
- Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Huntington's disease
- No development reported Cancer
Most Recent Events
- 01 Feb 2024 Phase-II clinical trials in Huntington's disease in Spain (PO) (NCT06469853)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in Spain
- 24 Aug 2023 Medibiofarma completes a phase I trial in Neurological disorders (In volunteers) in Spain (PO) (NCT06049147)